New Data on PatientReported Improvements in Quality of Life Measures and Other Clinical Responses in Moderate to Severe Rheumatoid Arthritis Patients Taking Cimzia certolizumab pegol Highlighted at American College of Rheumatology Meeting

ATLANTA Nov. 7 2011 PRNewswire UCB a leading biopharmaceutical company at the forefront of immunology treatment and research is proud to sponsor several key sets of Cimzia&174; certolizumab pegol data at the American College of Rheumatology's 2011 An...